Clinical Trials at Vanderbilt-Ingram Cancer Center
As of June 2026, 42 paid clinical trials are recruiting at Vanderbilt-Ingram Cancer Center, located at Vanderbilt-Ingram Cancer Center, 2220 Pierce Ave Suite 1710, Nashville, TN 37232, phone (615) 936-8422 in Nashville, Tennessee. Active studies at this site cover conditions such as Breast Cancer, Advanced Solid Tumor and Colorectal Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
42 clinical trials at Vanderbilt-Ingram Cancer Center
·Clear filters·↓ Download CSVA Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma
The Lilac Device Trial - IMPACT: A Clinical Investigation on IMproving Peripheral Neuropathy Induced by Chemotherapy With Advanced Compression Technology - A Safety and Efficacy Study
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Small Cell Lung Cancer Community Engagement to Eliminate Research Discepancies
A Study of PHST001 in Advanced Solid Tumors
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
SMP-3124LP in Adults With Advanced Solid Tumors
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
Study of CHS-114 in Participants With Advanced Solid Tumors
Genetics of Appendix Cancer Study
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer
Preserving Fertility After Colorectal Cancer Study
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
Hypofractionated Radiotherapy Followed by Surgical Resection in the Treatment of Soft Tissue Sarcomas
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Studying Health Outcomes After Treatment in Patients With Retinoblastoma
Inherited CAncer REgistry
Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides
Collecting and Storing Tissue Samples From Women With or Without Breast Cancer
Molecular Predictors of Cancer in Patients at High Risk of Lung Cancer
Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants
About research studies in Nashville
Nashville has approximately 1,421 recruiting research studies across a wide range of therapeutic areas. Tennessee is home to Vanderbilt University Medical Center and St. Jude Children's Research Hospital — world leaders in pediatric oncology and personalized medicine.
Common conditions studied in Nashville
- Breast Cancer (45 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Advanced Solid Tumor (33 active studies). Recruiting Advanced Solid Tumor studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Colorectal Cancer (29 active studies). Colorectal cancer trials explore novel chemotherapy combinations, targeted agents, and immunotherapy for microsatellite-instability-high tumors.
- Ovarian Cancer (26 active studies). Ovarian cancer research examines PARP inhibitors, maintenance therapies, and antibody-drug conjugates for recurrent and platinum-resistant disease.
- Advanced Solid Tumors (25 active studies). Recruiting Advanced Solid Tumors studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Multiple Myeloma (23 active studies). Recruiting Multiple Myeloma studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
Leading research sponsors in Nashville
- Vanderbilt University Medical Center
- AstraZeneca
- National Cancer Institute (NCI)
- Vanderbilt-Ingram Cancer Center
- Merck Sharp & Dohme LLC
Local regulations and guidelines
Clinical trials in Tennessee are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. Tennessee research additionally follows state public health department oversight and any applicable state privacy statutes.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in Nashville. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in Nashville
Hipa.ai aggregates every recruiting study in Nashville from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in Nashville?
There are approximately 1,421 recruiting clinical trials in Nashville, Tennessee listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Nashville pay participants?
Most recruiting trials in Nashville compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Nashville?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Nashville?
The most common conditions under active study in Nashville include Breast Cancer (45), Advanced Solid Tumor (33), Colorectal Cancer (29), Ovarian Cancer (26), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Nashville?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Nashville on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Nashville?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Nashville?
Recruiting research sites in Nashville include Vanderbilt University Medical Center, SCRI Oncology Partners, Vanderbilt University/Ingram Cancer Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Nashville right now?
The largest active categories in Nashville are Cancer & tumors (591), Cardiovascular (85), Neurology & pain (66). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Vanderbilt-Ingram Cancer Center?
Vanderbilt-Ingram Cancer Center is located at Vanderbilt-Ingram Cancer Center, 2220 Pierce Ave Suite 1710, Nashville, TN 37232. Use the Google Maps link in the intro above to get directions.
How do I contact Vanderbilt-Ingram Cancer Center?
You can reach Vanderbilt-Ingram Cancer Center by phone at (615) 936-8422. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.